Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

التفاصيل البيبلوغرافية
العنوان: Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
المؤلفون: Ruperto, Nicolino, Brunner, Hermine I, Synoverska, Olga, Ting, Tracy V, Mendoza, Carlos Abud, Spindler, Alberto, Vyzhga, Yulia, Marzan, Katherine, Grebenkina, Lyudmila, Tirosh, Irit, Imundo, Lisa, Jerath, Rita, Kingsbury, Daniel J, Sozeri, Betul, Vora, Sheetal S, Prahalad, Sampath, Zholobova, Elena, Butbul Aviel, Yonatan, Chasnyk, Vyacheslav, Lerman, Melissa, Nanda, Kabita, Schmeling, Heinrike, Tory, Heather, Uziel, Yosef, Viola, Diego O, Posner, Holly B, Kanik, Keith S, Wouters, Ann, Chang, Cheng, Zhang, Richard, Lazariciu, Irina, Hsu, Ming-Ann, Suehiro, Ricardo M, Martini, Alberto, Lovell, Daniel J, Cuttica, R, Akikusa, J, Chaitow, J, Wouters, C, Oliveira, S, Neiva, CLS, Santiago, M, Silva, CA, Terreri, MT, Magalhaes, C, De Souza, V, Bandeira, M, Chédeville, G, Houghton, K, Vazquez-Del Mercado, M, Rizo Rodriguez, J, Kobusinska, K, Alexeeva, E, Calvo Penades, I, Boteanu, AL, Kasapcopur, O, Poyrazoglu, MH, Erguven, M, Ozen, S, Al-Abadi, E, Bohnsack, J, Carrasco, R, Dare, J, Gottlieb, B, Wahezi, D, Jung, L, Klein-Gitelman, M, Zhang, Y, Wagner-Weiner, L, Tarvin, S, Vehe, RK, Chiraseveenuprapund, P, Rivas-Chacon, R, De La Pena, W, Sagcal-Gironella, ACP, Weiss, JE
المصدر: The Lancet; November-December 2021, Vol. 398 Issue: 10315 p1984-1996, 13p
مستخلص: Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic arthritis (JIA).
قاعدة البيانات: Supplemental Index
الوصف
تدمد:01406736
1474547X
DOI:10.1016/S0140-6736(21)01255-1